Arrowhead Pharmaceuticals.
biopharmaceutical company
- Reports this week
- 1
- Active events
- 0
- Connections
- 50
What's happening
Earlier this month
One to three months ago
-
Royal Bank of Canada reaffirmed rating, Citigroup began coverage, and Morgan Stanley boosted price target on Arrowhead Pharmaceuticals.Some support1 report
-
Nuvation Bio Inc. and Arrowhead Pharmaceuticals are under review regarding stock price volatility when compared to the S&P 500 index.Some support1 report
-
Career paths of individuals are detailed, including someone who started at Boston Consulting Group, someone who began at Deloitte & Touche LLP, and someone who previously worked at Arrowhead Pharmaceuticals and Intarcia Therapeutics.Some support1 report
Gone quiet
No new reports in 90+ days-
Morgan Stanley lifted its target price and gave an overweight rating for Arrowhead Pharmaceuticals, while Norges Bank acquired a new stake in the company's shares.Some support2 reports
-
Arrowhead Pharmaceuticals participated in the ESC Congress 2025.Some support3 reports
-
Berenberg Bank reaffirmed a buy rating on ACG Acquisition, and Stifel Nicolaus assumed coverage of the company.Some support2 reports
-
Arrowhead Pharmaceuticals stock is trading on the Nasdaq electronic exchange.Some support2 reports
-
FDA fast-tracking of a therapy involving Precision BioSciences, Arrowhead Pharmaceuticals, and Gilead Sciences began on July 1, 2025.Speculative1 report1 development inside
-
Arrowhead Pharmaceuticals issued a press release from its offices in Pasadena on June 23, 2025.Some support2 reports
-
Arrowhead Pharmaceuticals and Amgen are developing RNAi-based therapies for dyslipidemias.Speculative1 report
-
Arrowhead Pharmaceuticals began using Twitter, LinkedIn, and Instagram for company communication.Some support1 report
-
Arrowhead Pharmaceuticals approved inducement grants under NASDAQ Rule 5635(c)(4) on July 25, 2025.Some support1 report
-
Arrowhead Pharmaceuticals and Sarepta entered into a collaboration regarding siRNA programs, including licensing agreement payments starting on August 19, 2025.Well supported4 reports1 development inside
-
Arrowhead and Sarepta reached clinical and licensing milestones in their collaboration regarding siRNA programs.Some support1 report
-
Arrowhead Pharmaceuticals and Bayer are navigating the post-tariff future of clinical trials, discussing supply chains on the US West Coast.Some support1 report
-
Arrowhead Pharmaceuticals filed both NDA and MAA for plozasiran treatment on August 8, 2025.Some support1 report
-
Arrowhead received a milestone payment from Sarepta regarding their collaboration. Separately, Sanofi signed an asset purchase agreement with an Arrowhead subsidiary.Some support2 reports
-
Novartis gains exclusive rights to develop ARO-SNCA through a collaboration that validates Arrowhead's TRiM technology.Well supported3 reports1 development inside
-
Novartis entered a licensing deal with Arrowhead Pharmaceuticals to develop a treatment for Parkinson’s Disease.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Arrowhead Pharmaceuticals
Events traced to Arrowhead Pharmaceuticals, step by step, newest firstAround Arrowhead Pharmaceuticals this week
News at the entities that move Arrowhead Pharmaceuticals most-
Nasdaq StructuralAn AI stock sell-off impacted Nasdaq on November 5, 2026, following the election results.Moves Arrowhead Pharmaceuticals
-
FDA StructuralThe FDA approved Miplyffa for the treatment of Niemann-Pick disease.Moves Arrowhead Pharmaceuticals
-
Leerink partners Mentioned togetherLeerink Partners provided coverage and price targets for Freenome on September 26, 2026.Moves Arrowhead Pharmaceuticals
-
Securities and Exchange Commission StructuralStar Holdings sold a land parcel in Coney Island and filed its quarterly report with the SEC.Moves Arrowhead Pharmaceuticals
-
Novartis StructuralA study on cardiovascular health was presented at an American Heart Association meeting, sponsored by Novartis.Moves Arrowhead Pharmaceuticals
-
Royal Bank of Canada TransactionalRoyal Bank of Canada cut its target price for aTyr Pharma, which was reported by Benzinga.Moves Arrowhead Pharmaceuticals
Connections
The 16 strongest of 50, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Nasdaq Structural
Arrowhead Pharmaceuticals is formally listed on the Nasdaq stock exchange, establishing a functional dependency for public trading.
-
Novartis Structural
Novartis licensed Arrowhead's ARO-SNCA therapy, gaining exclusive rights for development and commercialization.
-
Sarepta Therapeutics Operational
The companies maintain a formal partnership for drug development, involving rights transfer, joint collaboration, and milestone payments.
-
FDA Structural
Arrowhead Pharmaceuticals is undergoing the formal regulatory approval process for plozasiran with the FDA.
-
Sarepta Operational
Arrowhead and Sarepta maintain an ongoing operational collaboration through licensing agreements and milestone payments.
-
Morgan Stanley Transactional
Morgan Stanley upgraded the target price and gave an overweight rating for Arrowhead Pharmaceuticals.
-
Leerink partners Mentioned together
Leerink partners issued a price target and rating for Arrowhead Pharmaceuticals.
-
Royal Bank of Canada Transactional
The relationship involves specific market actions by Royal Bank of Canada regarding Arrowhead Pharmaceuticals, including price target adjustments and rating reaffirmations.
Show all 16 connections
-
Ionis Pharmaceuticals Operational
The companies are active rivals competing for market efficacy in the hypertriglyceridemia therapeutic area.
-
Norges Bank Transactional
Norges Bank acquired a new stake in shares of Arrowhead Pharmaceuticals.
-
Securities and Exchange Commission Structural
Arrowhead Pharmaceuticals is subject to regulatory oversight and filing requirements by the Securities and Exchange Commission.
-
Citigroup Mentioned together
Citigroup began providing stock coverage and analysis for Arrowhead Pharmaceuticals.
-
China Shared context
Arrowhead's product, Plozasiran, has received approval to operate in the Chinese market.
-
MarketBeat Mentioned together
MarketBeat provides analyst ratings and market data for Arrowhead Pharmaceuticals.
-
Pasadena Shared context
Arrowhead Pharmaceuticals is located and headquartered in Pasadena.
-
California Shared context
The relationship is contextual, referencing a key figure's past association with the state of California.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
2 eventsShow 2 earlier months
July 2026
2 eventsJune 2026
14 events- Arrowhead Pharmaceuticals participated in the ESC Congress 2025.
- Arrowhead Pharmaceuticals stock is trading on the Nasdaq electronic exchange.
- FDA fast-tracking of a therapy involving Precision BioSciences, Arrowhead Pharmaceuticals, and Gilead Sciences began on July 1, 2025.
- Arrowhead Pharmaceuticals issued a press release from its offices in Pasadena on June 23, 2025.
- Arrowhead Pharmaceuticals and Amgen are developing RNAi-based therapies for dyslipidemias.
- Arrowhead Pharmaceuticals began using Twitter, LinkedIn, and Instagram for company communication.
- Arrowhead Pharmaceuticals approved inducement grants under NASDAQ Rule 5635(c)(4) on July 25, 2025.
- Arrowhead Pharmaceuticals and Sarepta entered into a collaboration regarding siRNA programs, including licensing agreement payments starting on August 19, 2025.
- Arrowhead and Sarepta reached clinical and licensing milestones in their collaboration regarding siRNA programs.
- Arrowhead Pharmaceuticals and Bayer are navigating the post-tariff future of clinical trials, discussing supply chains on the US West Coast.
- Arrowhead Pharmaceuticals filed both NDA and MAA for plozasiran treatment on August 8, 2025.
- Arrowhead received a milestone payment from Sarepta regarding their collaboration. Separately, Sanofi signed an asset purchase agreement with an Arrowhead subsidiary.
- Novartis gains exclusive rights to develop ARO-SNCA through a collaboration that validates Arrowhead's TRiM technology.
- Novartis entered a licensing deal with Arrowhead Pharmaceuticals to develop a treatment for Parkinson’s Disease.